• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Prioritization of risk groups for influenza vaccination in resource limited settings - A case study from South Africa

tetano

Editor, Senior Moderator
Vaccine. 2018 Nov 21. pii: S0264-410X(18)31573-1. doi: 10.1016/j.vaccine.2018.11.048. [Epub ahead of print]
[h=1]Prioritization of risk groups for influenza vaccination in resource limited settings - A case study from South Africa.[/h] McMorrow ML[SUP]1[/SUP], Tempia S[SUP]2[/SUP], Walaza S[SUP]3[/SUP], Treurnicht FK[SUP]4[/SUP], Ramkrishna W[SUP]5[/SUP], Azziz-Baumgartner E[SUP]6[/SUP], Madhi SA[SUP]7[/SUP], Cohen C[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Due to competing health priorities, low- and middle-income countries (LMIC) may need to prioritize between different influenza vaccine risk groups. Risk group prioritization may differ in LMIC based upon programmatic feasibility, country-specific prevalence of risk conditions and influenza-associated morbidity and mortality.
[h=4]METHODS:[/h] In South Africa, we collected local disease burden data (both published and unpublished) and published vaccine efficacy data in risk groups and healthy adults. We used these data to aid policy makers with risk group prioritization for influenza vaccination. We used the following formula to assess potential vaccine averted disease in each risk group: rate of influenza-associated hospitalization (or death) per 100,000 population * influenza vaccine efficacy (VE). We further estimated the cost per hospital day averted and the cost per year of life saved by influenza vaccination.
[h=4]RESULTS:[/h] Pregnant women, HIV-infected adults, and adults and children with tuberculosis disease had among the highest estimates of hospitalizations averted per 100,000 vaccinated and adults aged 65 years and older had the highest estimated deaths averted per 100,000 vaccinated. However, when assessing both the cost per hospital day averted (range: USD148-1,344) and the cost per year of life saved (range: USD112-1,230); adults and children with TB disease, HIV-infected adults and pregnant women had the lowest cost per outcome averted.
[h=4]DISCUSSION:[/h] An assessment of the potential disease outcomes averted and associated costs may aid policymakers in risk group prioritization for influenza vaccination.
Copyright ? 2018. Published by Elsevier Ltd.


[h=4]KEYWORDS:[/h] Hospitalization; Influenza; Mortality; South Africa; Vaccine policy

PMID: 30471956 DOI: 10.1016/j.vaccine.2018.11.048
 
Back
Top Bottom